National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019

GBD 2019 Iran Thyroid Cancer Collaborators

doi:10.1038/s41598-022-17115-0

National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019

GBD 2019 Iran Thyroid Cancer Collaborators

Tehran University of Medical Sciences
Karolinska Institutet
Shahid Beheshti University of Medical Sciences
Shahrekord University of Medical Sciences
Khomein University of Medical Sciences
Golestan University of Medical Sciences
Iran University of Medical Sciences
Zanjan University of Medical Sciences
School of Medicine
Babol University of Medical Sciences
Mazandaran University of Medical Sciences
Maastricht University
Shiraz University of Medical Sciences
Arak University of Medical Sciences
Isfahan University of Medical Sciences
Qazvin University of Medical Sciences
Sana Institute of Higher Education
Johns Hopkins University
Guilan University of Medical Sciences
Guilan University of Medical Sciences
Mashhad University of Medical Sciences
Baku State University
Moscow Pedagogical State University
The Iranian Academy of Medical Sciences
Saveh University of Medical Sciences
Kermanshah University of Medical Sciences
University of Padua
Associazione Italiana Ricerca Oncologica di Base AIROB (Italian Association of Basic Research Oncology)
Independent Consultant
Sirjan University of Medical Sciences
Kerman University of Medical Sciences
Birjand University of Medical Sciences
Universal Scientific Education and Research Network (USERN)
Rafsanjan University of Medical Sciences
Sina Medical Biochemistry Technologies
University of Washington

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

13 Citas (Scopus)

Resumen

An updated exploration of the burden of thyroid cancer across a country is always required for making correct decisions. The objective of this study is to present the thyroid cancer burden and attributed burden to the high Body Mass Index (BMI) in Iran at national and sub-national levels from 1990 to 2019. The data was obtained from the GBD 2019 study estimates. To explain the pattern of changes in incidence from 1990 to 2019, decomposition analysis was conducted. Besides, the attribution of high BMI in the thyroid cancer DALYs and deaths were obtained. The age-standardized incidence rate of thyroid cancer was 1.57 (95% UI: 1.33–1.86) in 1990 and increased 131% (53–191) until 2019. The age-standardized prevalence rate of thyroid cancer was 30.19 (18.75–34.55) in 2019 which increased 164% (77–246) from 11.44 (9.38–13.85) in 1990. In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.49 (0.36–0.53), and 13.16 (8.93–14.62), respectively. These numbers also increased since 1990. The DALYs and deaths attributable to high BMI was 1.91 (0.95–3.11) and 0.07 (0.04–0.11), respectively. The thyroid cancer burden and high BMI attributed burden has increased from 1990 to 2019 in Iran. This study and similar studies’ results can be used for accurate resource allocation for efficient management and all potential risks’ modification for thyroid cancer with a cost-conscious view.

Idioma original	Inglés
Número de artículo	13231
Publicación	Scientific Reports
Volumen	12
N.º	1
DOI	https://doi.org/10.1038/s41598-022-17115-0
Estado	Publicada - dic. 2022
Publicado de forma externa	Sí

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

ODS 3: Salud y bienestar

Acceder al documento

10.1038/s41598-022-17115-0

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{ffc82d46687e4fddbbde80056a9a6c62,

title = "National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019",

abstract = "An updated exploration of the burden of thyroid cancer across a country is always required for making correct decisions. The objective of this study is to present the thyroid cancer burden and attributed burden to the high Body Mass Index (BMI) in Iran at national and sub-national levels from 1990 to 2019. The data was obtained from the GBD 2019 study estimates. To explain the pattern of changes in incidence from 1990 to 2019, decomposition analysis was conducted. Besides, the attribution of high BMI in the thyroid cancer DALYs and deaths were obtained. The age-standardized incidence rate of thyroid cancer was 1.57 (95\% UI: 1.33–1.86) in 1990 and increased 131\% (53–191) until 2019. The age-standardized prevalence rate of thyroid cancer was 30.19 (18.75–34.55) in 2019 which increased 164\% (77–246) from 11.44 (9.38–13.85) in 1990. In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.49 (0.36–0.53), and 13.16 (8.93–14.62), respectively. These numbers also increased since 1990. The DALYs and deaths attributable to high BMI was 1.91 (0.95–3.11) and 0.07 (0.04–0.11), respectively. The thyroid cancer burden and high BMI attributed burden has increased from 1990 to 2019 in Iran. This study and similar studies{\textquoteright} results can be used for accurate resource allocation for efficient management and all potential risks{\textquoteright} modification for thyroid cancer with a cost-conscious view.",

author = "\{GBD 2019 Iran Thyroid Cancer Collaborators\} and Mohammadreza Azangou-Khyavy and \{Saeedi Moghaddam\}, Sahar and Negar Rezaei and Zahra Esfahani and Nazila Rezaei and Sina Azadnajafabad and Rashidi, \{Mohammad Mahdi\} and Esmaeil Mohammadi and Mohammadreza Azangou-Khyavy and Moghaddam, \{Sahar Saeedi\} and Zahra Esfahani and Sina Azadnajafabad and Rashidi, \{Mohammad Mahdi\} and Esmaeil Mohammadi and Mohsen Abbasi-Kangevari and Zeinab Abbasi-Kangevari and Hassan Abolhassani and Sepideh Ahmadi and Ali Ahmadi and Saeed Amini and Amlashi, \{Fazel Isapanah\} and Anoushirvani, \{Ali Arash\} and Jalal Arabloo and Athari, \{Seyyed Shamsadin\} and Jafari, \{Amirhossein Azari\} and Sima Besharat and Ali Bijani and Ahmad Daryani and Mostafa Dianatinasab and Mojtaba Didehdar and Ali Fatehizadeh and Ghamari, \{Seyyed Hadi\} and Ahmad Ghashghaee and Pouya Goleij and Mohamad Golitaleb and Nima Hafezi-Nejad and Arvin Haj-Mirzaian and Soheil Hassanipour and Ali Kabir and Maryam Keramati and Rovshan Khalilov and Maryam Khayamzadeh and Kolahi, \{Ali Asghar\} and Farzad Kompani and Koohestani, \{Hamid Reza\} and Somayeh Livani and Soleiman Mahjoub and Malekpour, \{Mohammad Reza\} and Narges Malih and Javad Sharifi-Rad",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = dec,

doi = "10.1038/s41598-022-17115-0",

language = "Ingl{\'e}s",

volume = "12",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019

AU - GBD 2019 Iran Thyroid Cancer Collaborators

AU - Azangou-Khyavy, Mohammadreza

AU - Saeedi Moghaddam, Sahar

AU - Rezaei, Negar

AU - Esfahani, Zahra

AU - Rezaei, Nazila

AU - Azadnajafabad, Sina

AU - Rashidi, Mohammad Mahdi

AU - Mohammadi, Esmaeil

AU - Azangou-Khyavy, Mohammadreza

AU - Moghaddam, Sahar Saeedi

AU - Esfahani, Zahra

AU - Azadnajafabad, Sina

AU - Rashidi, Mohammad Mahdi

AU - Mohammadi, Esmaeil

AU - Abbasi-Kangevari, Mohsen

AU - Abbasi-Kangevari, Zeinab

AU - Abolhassani, Hassan

AU - Ahmadi, Sepideh

AU - Ahmadi, Ali

AU - Amini, Saeed

AU - Amlashi, Fazel Isapanah

AU - Anoushirvani, Ali Arash

AU - Arabloo, Jalal

AU - Athari, Seyyed Shamsadin

AU - Jafari, Amirhossein Azari

AU - Besharat, Sima

AU - Bijani, Ali

AU - Daryani, Ahmad

AU - Dianatinasab, Mostafa

AU - Didehdar, Mojtaba

AU - Fatehizadeh, Ali

AU - Ghamari, Seyyed Hadi

AU - Ghashghaee, Ahmad

AU - Goleij, Pouya

AU - Golitaleb, Mohamad

AU - Hafezi-Nejad, Nima

AU - Haj-Mirzaian, Arvin

AU - Hassanipour, Soheil

AU - Kabir, Ali

AU - Keramati, Maryam

AU - Khalilov, Rovshan

AU - Khayamzadeh, Maryam

AU - Kolahi, Ali Asghar

AU - Kompani, Farzad

AU - Koohestani, Hamid Reza

AU - Livani, Somayeh

AU - Mahjoub, Soleiman

AU - Malekpour, Mohammad Reza

AU - Malih, Narges

AU - Sharifi-Rad, Javad

PY - 2022/12

Y1 - 2022/12

N2 - An updated exploration of the burden of thyroid cancer across a country is always required for making correct decisions. The objective of this study is to present the thyroid cancer burden and attributed burden to the high Body Mass Index (BMI) in Iran at national and sub-national levels from 1990 to 2019. The data was obtained from the GBD 2019 study estimates. To explain the pattern of changes in incidence from 1990 to 2019, decomposition analysis was conducted. Besides, the attribution of high BMI in the thyroid cancer DALYs and deaths were obtained. The age-standardized incidence rate of thyroid cancer was 1.57 (95% UI: 1.33–1.86) in 1990 and increased 131% (53–191) until 2019. The age-standardized prevalence rate of thyroid cancer was 30.19 (18.75–34.55) in 2019 which increased 164% (77–246) from 11.44 (9.38–13.85) in 1990. In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.49 (0.36–0.53), and 13.16 (8.93–14.62), respectively. These numbers also increased since 1990. The DALYs and deaths attributable to high BMI was 1.91 (0.95–3.11) and 0.07 (0.04–0.11), respectively. The thyroid cancer burden and high BMI attributed burden has increased from 1990 to 2019 in Iran. This study and similar studies’ results can be used for accurate resource allocation for efficient management and all potential risks’ modification for thyroid cancer with a cost-conscious view.

AB - An updated exploration of the burden of thyroid cancer across a country is always required for making correct decisions. The objective of this study is to present the thyroid cancer burden and attributed burden to the high Body Mass Index (BMI) in Iran at national and sub-national levels from 1990 to 2019. The data was obtained from the GBD 2019 study estimates. To explain the pattern of changes in incidence from 1990 to 2019, decomposition analysis was conducted. Besides, the attribution of high BMI in the thyroid cancer DALYs and deaths were obtained. The age-standardized incidence rate of thyroid cancer was 1.57 (95% UI: 1.33–1.86) in 1990 and increased 131% (53–191) until 2019. The age-standardized prevalence rate of thyroid cancer was 30.19 (18.75–34.55) in 2019 which increased 164% (77–246) from 11.44 (9.38–13.85) in 1990. In 2019, the death rate, and Disability-adjusted life years of thyroid cancer was 0.49 (0.36–0.53), and 13.16 (8.93–14.62), respectively. These numbers also increased since 1990. The DALYs and deaths attributable to high BMI was 1.91 (0.95–3.11) and 0.07 (0.04–0.11), respectively. The thyroid cancer burden and high BMI attributed burden has increased from 1990 to 2019 in Iran. This study and similar studies’ results can be used for accurate resource allocation for efficient management and all potential risks’ modification for thyroid cancer with a cost-conscious view.

UR - https://www.scopus.com/pages/publications/85135435122

U2 - 10.1038/s41598-022-17115-0

DO - 10.1038/s41598-022-17115-0

M3 - Artículo

C2 - 35918489

AN - SCOPUS:85135435122

SN - 2045-2322

VL - 12

JO - Scientific Reports

JF - Scientific Reports

IS - 1

M1 - 13231

ER -

National, sub-national, and risk-attributed burden of thyroid cancer in Iran from 1990 to 2019

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto